KFF September 6, 2024
Matt McGough, Justin Lo, Delaney Tevis, Matthew Rae, Cynthia Cox

More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis.

Though only about 3% of adults with employer coverage had a prescription in 2022, demand for and spending on GLP-1 drugs has grown and could...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Insurance, Patient / Consumer, Payer, Pharma / Biotech, Survey / Study, Trends
Childhood long COVID might be caused by lower blood flow in lungs, scans suggest
Technology shapes relationships. Relationships shape technology.
How Insurance Claim Denials Harm Patients’ Health, Finances
Sounding the Alarm on the Human Cost of Medical Debt
Can AI predict the next pandemic? A new study says yes

Share This Article